according to below, next to no subset of biopharma has been immune the last couple of months (ignoring Feb) from heavy pull backs. On the other hand, the top 500 biotechs are becoming increasingly cashed up. Hopefully macro side of things calms down coinciding with positive news flow over the next 12 months into a hungry Biotech M & A sector.
according to below, next to no subset of biopharma has been...
-
- There are more pages in this discussion • 6,180 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
